AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8990504 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (Betnovate)
Number of subjects: 10
Study 8990504 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (Daivonex)
Number of subjects: 10
Study 8990504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure nanocolloid gel
Number of subjects: 10
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute curative resection
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative curative resection
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative non-curative resection
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute non-curative resection
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TAE (Transarterial Embolization)
Number of subjects: 121
Study 1333899 — intervention group
Group type: COMPARATOR
Intervention: Non-TAE
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE (Percutaneous Sclerotherapy)
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy after PSE
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Reresection in recurrent HCC
Number of subjects: 121
Study 1333899 — intervention group
Group type: COMPARATOR
Intervention: TAE in recurrent HCC
Number of subjects: 121
Study 1333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial infusion of 5-FU and lentinan with intermittent epirubicin
Number of subjects: 121
Study 6379275 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASS) 100 mg/day
Number of subjects: 60
Study 6379275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30220261 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced-PE (S-PE; 10 sessions over 8 weeks)
Number of subjects: 326
Study 30220261 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed-PE (M-PE; 10 sessions over 2 weeks)
Number of subjects: 326
Study 30220261 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT; 10 sessions over 8 weeks)
Number of subjects: 326
Study 29297076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically Expanded Valve (MEV)
Number of subjects: 912
Study 29297076 — intervention group
Group type: COMPARATOR
Intervention: Self-Expanding Valve (SEV)
Number of subjects: 912
Study 26289619 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenanthramides (AVA) supplementation (9.2 mg AVA per day)
Number of subjects: 16
Study 26289619 — intervention group
Group type: COMPARATOR
Intervention: Control (0.4 mg AVA per day)
Number of subjects: 16
Study 24316175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.2mg QID
Number of subjects: 18
Study 24316175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.8mg QID
Number of subjects: 18
Study 24316175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24316175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (20mg and 40mg)
Number of subjects: 18
Study 22002961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol (15 mg for subjects <65 years and 10 mg for subjects ≥65 years)
Number of subjects: 101
Study 22002961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 101
Study 22002961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 20174968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 40
Study 20174968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17606555 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk intake (at least some human milk)
Number of subjects: 1057
Study 17606555 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk intake (mean volume)
Number of subjects: 1057
Study 17606555 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk intake (mean proportional volume)
Number of subjects: 1057
Study 16446317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles)
Number of subjects: 108
Study 16446317 — intervention group
Group type: COMPARATOR
Intervention: Modified version of ProMECE-CytaBOM chemotherapy (seq-PC)
Number of subjects: 108
Study 12544979 — intervention group
Group type: EXPERIMENTAL
Intervention: rh granulocyte colony-stimulating factor (Filgrastim)
Number of subjects: 0
Study 12544979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10565592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 40
Study 10565592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8653312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy (group A)
Number of subjects: 225
Study 8653312 — intervention group
Group type: COMPARATOR
Intervention: No adrenalectomy (group B)
Number of subjects: 225
Study 1712801 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% low molecular weight hydroxyethyl starch (LMW HES)
Number of subjects: 18
Study 1712801 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 18
Study 6362943 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling by a specialist nurse
Number of subjects: 152
Study 6362943 — intervention group
Group type: COMPARATOR
Intervention: Standard care from the surgical unit
Number of subjects: 152
Study 31918579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 390
Study 31918579 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 390
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MVr) with papillary muscle approximation (PMA)
Number of subjects: 48
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary artery systolic pressure
Number of subjects: 48
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: MV tenting area
Number of subjects: 48
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric MV tethering pattern
Number of subjects: 48
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter
Number of subjects: 48
Study 30684477 — intervention group
Group type: EXPERIMENTAL
Intervention: MV tenting area ≥ 3.1 cm2 and left ventricular end-diastolic diameter ≥ 64 mm
Number of subjects: 48
Study 27748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressed condition
Number of subjects: 53
Study 27748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhearing Two Adults condition
Number of subjects: 53
Study 27748212 — intervention group
Group type: COMPARATOR
Intervention: Overhearing Classroom condition
Number of subjects: 53
Study 28327266 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (8g per 200 mL milk once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (4g per 100 mL milk twice per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (8g per 200 mL milk once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (4g per 100 mL milk twice per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (8g per 200 mL milk once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (twice per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (twice per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (once per day)
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Xylitol vs Sucrose
Number of subjects: 153
Study 28327266 — intervention group
Group type: COMPARATOR
Intervention: Xylitol vs Sorbitol
Number of subjects: 153
Study 25150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Change Techniques (BCTs) including intention formation, barrier identification, specific goal setting, instruction, general encouragement, self-monitoring of behaviour, social support, review of behavioural goals, and relapse prevention.
Number of subjects: 22
Study 21711438 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-BLC
Number of subjects: 362
Study 21711438 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 362
Study 19171274 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic intervention of the first MTP joint (group 1)
Number of subjects: 28
Study 19171274 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (group 2)
Number of subjects: 28
Study 17145137 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg T enanthate
Number of subjects: 57
Study 17145137 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg T enanthate
Number of subjects: 57
Study 17145137 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg T enanthate
Number of subjects: 57
Study 17145137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 57
Study 15824416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tam-IVF
Number of subjects: 60
Study 15824416 — intervention group
Group type: EXPERIMENTAL
Intervention: TamFSH-IVF
Number of subjects: 60
Study 15824416 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole-IVF
Number of subjects: 60
Study 15824416 — intervention group
Group type: COMPARATOR
Intervention: IVF (combined TamFSH-IVF and Letrozole-IVF)
Number of subjects: 60
Study 11719309 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/d for Week 1; 400 mg/d for Weeks 2 to 4)
Number of subjects: 157
Study 11719309 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 157
Study 11719309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9387176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-ridge Molteno implant
Number of subjects: 30
Study 9387176 — intervention group
Group type: COMPARATOR
Intervention: Standard Molteno implant with suture ligation
Number of subjects: 30
Study 9387176 — intervention group
Group type: COMPARATOR
Intervention: Suture-ligation implant group
Number of subjects: 30
Study 9387176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-ridge implant group
Number of subjects: 30
Study 7935033 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/day of conjugated equine oestrogen (CEE) cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Number of subjects: 36
Study 7935033 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day of transdermal oestradiol cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Number of subjects: 36
Study 7935033 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of CEE + 5 mg/day of MPA uninterruptedly
Number of subjects: 36
Study 7935033 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 36
Study 3513821 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted with HLA-A and HLA-B antigen matched material
Number of subjects: 40
Study 3513821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not grafted with matched material)
Number of subjects: 40
Study 29952241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration stimulus (n = 14), low-frequency and low-magnitude (27-32 Hz, 0.3 g), 20 minutes, 3 times per week for 12 weeks
Number of subjects: 31
Study 29952241 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n = 17)
Number of subjects: 31
Study 27157469 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g soy protein isolate (SP20)
Number of subjects: 8
Study 27157469 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy protein isolate (SP40)
Number of subjects: 8
Study 27157469 — intervention group
Group type: COMPARATOR
Intervention: 0 g soy protein isolate (SP0)
Number of subjects: 8
Study 24983201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-concordant intervention
Number of subjects: 216
Study 24170641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (800 kcal/day) for 28 days
Number of subjects: 20
Study 24170641 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 20
Study 21380981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LIEX)
Number of subjects: 45
Study 21380981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIEX)
Number of subjects: 45
Study 21380981 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study 18312089 — intervention group
Group type: EXPERIMENTAL
Intervention: Guglielmi detachable coils (GDCs)
Number of subjects: 92
Study 18312089 — intervention group
Group type: COMPARATOR
Intervention: Short-term follow-up angiograms
Number of subjects: 92
Study 16562415 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 700
Study 16562415 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 700
Study 12686247 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-LASIK group
Number of subjects: 32
Study 10928300 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 10928300 — intervention group
Group type: COMPARATOR
Intervention: Conventional agents and calcium channel blockers
Number of subjects: 0
Study 9370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitacre 25G
Number of subjects: 681
Study 9370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymedic 25G
Number of subjects: 681
Study 9370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte 24G
Number of subjects: 681
Study 9370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymedic 24G
Number of subjects: 681
Study 1555618 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recordings in the coronary care unit (CCU) performed for 24 hours
Number of subjects: 198
Study 1555618 — intervention group
Group type: EXPERIMENTAL
Intervention: ST recordings before discharge during ambulation in hospital (4-6 days after admission)
Number of subjects: 198
Study 1555618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring after 1 month
Number of subjects: 198
Study 6753245 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (400 mg/m2) administered with each of the 30 fractions of radiotherapy
Number of subjects: 102
Study 6753245 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered with each of the 30 fractions of radiotherapy
Number of subjects: 102
Study 31719145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubacin
Number of subjects: 0
Study 28912639 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine only (0.5%) 0.4 mg·kg‐1
Number of subjects: 90
Study 28912639 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (0.5%) 0.4 mg·kg‐1 + adrenaline (1:200,000)
Number of subjects: 90
Study 25571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective short-term message (ASM)
Number of subjects: 596
Study 25571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive long-term message
Number of subjects: 596
Study 25571997 — intervention group
Group type: COMPARATOR
Intervention: No message control
Number of subjects: 596
Study 25571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cognitive message
Number of subjects: 596
Study 25571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term affective message
Number of subjects: 596
Study 25571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cognitive message
Number of subjects: 596
Study 24156304 — intervention group
Group type: EXPERIMENTAL
Intervention: VisThesia™
Number of subjects: 44
Study 24156304 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat®
Number of subjects: 44
Study 21610205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release (ER) formulation (4 hours)
Number of subjects: 0
Study 21610205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release (ER) formulation (6 hours)
Number of subjects: 0
Study 21610205 — intervention group
Group type: COMPARATOR
Intervention: M-ER (comparator ER tablet)
Number of subjects: 0
Study 19207348 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based alcohol education intervention consisting of four interactive lessons, booklets for students and parents.
Number of subjects: 1686
Study 19207348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1686
Study 17457961 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg GBE complexed with phosphatidylserine
Number of subjects: 28
Study 17457961 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg GBE complexed with phosphatidylcholine
Number of subjects: 28
Study 17457961 — intervention group
Group type: COMPARATOR
Intervention: 120 mg GBE
Number of subjects: 28
Study 17457961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16449074 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy plus one Botulinum Toxin A injection
Number of subjects: 41
Study 16449074 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy only
Number of subjects: 41
Study 14501381 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of selenized yeast
Number of subjects: 0
Study 14501381 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of selenized yeast
Number of subjects: 0
Study 14501381 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 14501381 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenized yeast (both doses)
Number of subjects: 0
Study 10323688 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of sulbactam‐ampicillin combination
Number of subjects: 1400
Study 10323688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 1400
Study 8904729 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination group (high stress)
Number of subjects: 30
Study 8904729 — intervention group
Group type: COMPARATOR
Intervention: Nonexamination group (low stress)
Number of subjects: 30
Study 1930858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 40 mg/day for 8 weeks)
Number of subjects: 36
Study 1930858 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5 to 75 mg/day for 8 weeks)
Number of subjects: 36
Study 7172738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotion V
Number of subjects: 0
Study 7172738 — intervention group
Group type: COMPARATOR
Intervention: Lotion K
Number of subjects: 0
Study 31808996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing prior to statin initiation
Number of subjects: 0
Study 31808996 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 0
Study 29794609 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated internet-based pain coping skills training (PCST) program
Number of subjects: 144
Study 29794609 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education and PCST
Number of subjects: 144
Study 29794609 — intervention group
Group type: COMPARATOR
Intervention: Online education only (comparison group)
Number of subjects: 144
Study 29794609 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST group
Number of subjects: 144
Study 28741716 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA™ Proseal (PLMA)
Number of subjects: 0
Study 28741716 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA™ Supreme (SLMA)
Number of subjects: 0
Study 28741716 — intervention group
Group type: COMPARATOR
Intervention: Lateral position with pneumoperitoneum
Number of subjects: 0
Study 28741716 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 0
Study 26614499 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-tablet dose of IR/ER HB/APAP under fed (high- and low-fat) conditions
Number of subjects: 78
Study 26614499 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-tablet dose of IR/ER HB/APAP under fed (high- and low-fat) conditions
Number of subjects: 78
Study 26614499 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 78
Study 26614499 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 78
Study 26614499 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 78
Study 24035949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment followed by succinylcholine
Number of subjects: 60
Study 24035949 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine alone
Number of subjects: 60
Study 21635709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years monotherapy)
Number of subjects: 8010
Study 21635709 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 years monotherapy)
Number of subjects: 8010
Study 21635709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years followed by Letrozole for 3 years
Number of subjects: 8010
Study 21635709 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 2 years followed by Tamoxifen for 3 years
Number of subjects: 8010
Study 18503103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate analysis (n=1496)
Number of subjects: 2992
Study 18503103 — intervention group
Group type: COMPARATOR
Intervention: pH analysis (n=1496)
Number of subjects: 2992
Study 15665204 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast ankle brace
Number of subjects: 50
Study 15665204 — intervention group
Group type: COMPARATOR
Intervention: Elastic support bandage
Number of subjects: 50
Study 13679822 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 32
Study 13679822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32